Literature DB >> 18154959

Natriuretic peptides.

Lori B Daniels1, Alan S Maisel.   

Abstract

Natriuretic peptides (NPs) are released from the heart in response to pressure and volume overload. B-type natriuretic peptide (BNP) and N-terminal-proBNP have become important diagnostic tools for assessing patients who present acutely with dyspnea. The NP level reflects a compilation of systolic and diastolic function as well as right ventricular and valvular function. Studies suggest that using NPs in the emergency department can reduce the consumption of hospital resources and can lower costs by either eliminating the need for other, more expensive tests or by establishing an alternative diagnosis that does not require hospital stay. Caveats such as body mass index and renal function must be taken into account when analyzing NP levels. Natriuretic peptide levels have important prognostic value in multiple clinical settings, including in patients with stable coronary artery disease and with acute coronary syndromes. In patients with decompensated heart failure due to volume overload, a treatment-induced drop in wedge pressure is often accompanied by a rapid drop in NP levels. Knowing a patient's NP levels might thus assist with hemodynamic assessment and subsequent treatment titration. Monitoring NP levels in the outpatient setting might also improve patient care and outcomes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18154959     DOI: 10.1016/j.jacc.2007.09.021

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  261 in total

Review 1.  Plasma B-type natriuretic peptides in children with cardiovascular diseases.

Authors:  Bibhuti B Das
Journal:  Pediatr Cardiol       Date:  2010-10-07       Impact factor: 1.655

2.  Assessment of preoperative B-type natriuretic peptide in adult surgeries: is it useful?

Authors:  Amanda A Fox; Simon C Body
Journal:  Anesth Analg       Date:  2011-05       Impact factor: 5.108

Review 3.  Glutamate synthase: a fascinating pathway from L-glutamine to L-glutamate.

Authors:  R H H van den Heuvel; B Curti; M A Vanoni; A Mattevi
Journal:  Cell Mol Life Sci       Date:  2004-03       Impact factor: 9.261

4.  N-terminal pro-brain natriuretic peptide could be a marker of subclinical atherosclerosis in patients with type 2 diabetes.

Authors:  Takafumi Senmaru; Michiaki Fukui; Muhei Tanaka; Kazumi Sakabe; Emi Ushigome; Mai Asano; Masahiro Yamazaki; Goji Hasegawa; Naoto Nakamura
Journal:  Heart Vessels       Date:  2012-01-11       Impact factor: 2.037

Review 5.  ST2: a novel remodeling biomarker in acute and chronic heart failure.

Authors:  Ravi V Shah; James L Januzzi
Journal:  Curr Heart Fail Rep       Date:  2010-03

Review 6.  Control of autocrine and paracrine myocardial signals: an emerging therapeutic strategy in heart failure.

Authors:  Vincenzo Lionetti; Giacomo Bianchi; Fabio A Recchia; Carlo Ventura
Journal:  Heart Fail Rev       Date:  2010-11       Impact factor: 4.214

7.  Effect of sialylated O-glycans in pro-brain natriuretic peptide stability.

Authors:  Jingjing Jiang; Nicole Pristera; Wei Wang; Xiumei Zhang; Qingyu Wu
Journal:  Clin Chem       Date:  2010-03-26       Impact factor: 8.327

Review 8.  Natriuretic peptides in the management of aortic stenosis.

Authors:  Jutta Bergler-Klein
Journal:  Curr Cardiol Rep       Date:  2009-03       Impact factor: 2.931

9.  Predictive value of heart rate recovery after exercise testing in addition to brain natriuretic peptide levels in ambulatory patients with nonischemic dilated cardiomyopathy.

Authors:  Norihiro Shinoda; Akihiro Hirashiki; Takahiro Okumura; Rie Okamoto; Xian Wu Cheng; Yuji Kono; Kyosuke Takeshita; Sumio Yamada; Toyoaki Murohara
Journal:  Ann Noninvasive Electrocardiol       Date:  2012-08-13       Impact factor: 1.468

10.  Prognostic impact of the serum heart-type fatty acid-binding protein (H-FABP) levels in patients admitted to the non-surgical intensive care unit.

Authors:  Akihiro Shirakabe; Nobuaki Kobayashi; Noritake Hata; Masanori Yamamoto; Takuro Shinada; Kazunori Tomita; Masafumi Tsurumi; Masato Matsushita; Hirotake Okazaki; Yoshiya Yamamoto; Shinya Yokoyama; Kuniya Asai; Wataru Shimizu
Journal:  Clin Res Cardiol       Date:  2014-05-10       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.